Page last updated: 2024-11-08

bacampicillin

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

bacampicillin: ester prodrug that is hydrolyzed to ampicillin after its absorption from the gastrointestinal tract; RN given refers to parent cpd; structure [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

bacampicillin : A penicillanic acid ester that is the 1-ethoxycarbonyloxyethyl ester of ampicillin. It is a semi-synthetic, microbiologically inactive prodrug of ampicillin. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID441397
CHEMBL ID1583
CHEBI ID2968
SCHEMBL ID33818
MeSH IDM0058171

Synonyms (56)

Synonym
BRD-A41698174-003-03-9
BPBIO1_000410
NCGC00179582-01
D07487
penglobe (tn)
bacampicillin (inn)
PRESTWICK2_000416
BSPBIO_000372
C08122 ,
bacampicillin
50972-17-3
1'-ethoxycarbonyloxyethyl-(6-d-alpha-aminophenylacetamido)penicillanate
DB01602
1-[(ethoxycarbonyl)oxy]ethyl (2s,5r,6r)-6-{[(2r)-2-amino-2-phenylacetyl]amino}-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylate
PRESTWICK3_000416
bapc
penglobe
1-ethoxycarbonyloxyethyl (2s,5r,6r)-6((r)-(2-amino-2-phenylacetamido)-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo(3.2.0)heptan-2-carboxylat
bacampicillinum [inn-latin]
4-thia-1-azabicyclo(3.2.0)heptane-2-carboxylic acid, 6-((aminophenylacetyl)amino)-3,3-dimethyl-7-oxo-, 1-((ethoxycarbonyl)oxy)ethyl ester, (2s-(2alpha,5alpha,6beta(s*)))-
bacampicilina [inn-spanish]
(2s,5r,6r)-6((r)-(2-amino-2-phenylacetamido))-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo(3.2.0)heptane-2-carboxylic acid ester with ethyl 1-hydroxyethylcarbonate
6-((r)-2-amino-2-phenylacetamido)penicillansaeure-(1-(ethoxycarbonyloxy)ethylester
bacampicillin [inn:ban]
bacampicilline [inn-french]
PRESTWICK0_000416
PRESTWICK1_000416
SPBIO_002311
CHEBI:2968 ,
bacampicillinum
bacampicilline
1-[(ethoxycarbonyl)oxy]ethyl 6beta-[(2r)-2-amino-2-phenylacetamido]-2,2-dimethylpenam-3alpha-carboxylate
bacampicilina
CHEMBL1583
1-ethoxycarbonyloxyethyl (2s,5r,6r)-6-[[(2r)-2-amino-2-phenylacetyl]amino]-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylate
PFOLLRNADZZWEX-FFGRCDKISA-N
A828376
1-ethoxycarbonyloxyethyl (2s,5r,6r)-6-[[(2r)-2-amino-2-phenyl-acetyl]amino]-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylate;bacampicillin
8gm2j22278 ,
unii-8gm2j22278
EPITOPE ID:117129
SCHEMBL33818
bacampicillin [who-dd]
bacampicillin [inn]
4-thia-1-azabicyclo(3.2.0)heptane-2-carboxylic acid, 6-((aminophenylacetyl)amino)-3,3-dimethyl-7-oxo-, 1-((ethoxycarbonyl)oxy)ethyl ester, (2s-(2.alpha.,5.alpha.,6.beta.(s*)))-
bacampicillin [mi]
bacampicillin [vandf]
CS-4753
DTXSID2048030
HY-B1149
1-[(ethoxycarbonyl)oxy]ethyl (2s,5r,6r)-6-[(2r)-2-amino-2-phenylacetamido]-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylate
AKOS030526153
(2s,5r,6r)-1-(ethoxycarbonyloxy)ethyl 6-((r)-2-amino-2-phenylacetamido)-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylate
Q2878140
EN300-19766307
gtpl12292

Research Excerpts

Overview

Bacampicillin is a prodrug of ampicillin, the concentration of which was determined in plasma and urine by bioassay. It is an ester prodrug that is hydrolyzed toAmpicillin after its absorption from the gastrointestinal tract.

ExcerptReferenceRelevance
"Bacampicillin (BAPC) is a esterified derivative of ampicillin (ABPC) developed recently by the Swedish company. "( [Experimental investigation on intrapulmonary and tracheobronchial distribution of ampicillin after administration of a beta-lactam antibiotic, bacampicillin].
Hsu, LH; Ishihara, Y; Kitamura, S; Takaku, F, 1983
)
1.91
"Bacampicillin is a prodrug of ampicillin, the concentration of which was determined in plasma and urine by bioassay."( Correlation between the bioavailability of microencapsulated bacampicillin hydrochloride in suspension and in vitro microcapsule dissolution.
Huitfeldt, B; Nyqvist, H; Sjöqvist, R; Sjövall, J, 1984
)
1.23
"Bacampicillin hydrochloride is an orally administered ester of ampicillin that is rapidly and completely hydrolyzed in vivo to ampicillin. "( Bacampicillin hydrochloride: chemistry, pharmacology, and clinical use.
Neu, HC; Scheife, RT,
)
3.02
"Bacampicillin is an ethoxycarbonyloxyethyl ester of ampicillin that is rapidly converted to free ampicillin, the active agent, by nonspecific esterases present in serum and in the intestinal wall. "( The pharmacokinetics of bacampicillin.
Neu, HC,
)
1.88
"Bacampicillin is a recently synthesized prodrug of ampicillin. "( Clinical pharmacokinetic evaluation of bacampicillin.
Braga, PC; Ceccarelli, G; Fraschini, F; Scaglione, F; Scarpazza, G, 1981
)
1.97
"Bacampicillin hydrochloride is an ester prodrug that is hydrolyzed to ampicillin after its absorption from the gastrointestinal tract. "( Pharmacokinetics of bacampicillin in equids.
McKellar, QA; Sarasola, P, 1995
)
2.06

Effects

ExcerptReferenceRelevance
"Bacampicillin hydrochloride has been microencapsulated to mask its very bitter taste. "( In vitro-in vivo evaluation of bacampicillin hydrochloride from microcapsules of water-insoluble and an acid-soluble polymer.
Nyqvist, H; Sjöqvist, R; Sjövall, J; Westerlund, D,
)
1.86

Treatment

ExcerptReferenceRelevance
"Bacampicillin treatment practically did not have an effect on the faecal flora."( A comparative study of the effect of oral treatment with augmentin, amoxycillin and bacampicillin on the faecal flora in mice.
Hofstra, W; Van der Waaij, D; Welling, GW, 1988
)
1.22

Toxicity

ExcerptReferenceRelevance
" Adverse drug reactions due to bacampicillin at all dose levels were less frequent than those of other anti-microbials."( The clinical efficacy and safety of bacampicillin twice daily in comparative studies.
Blomqvist, M; Hedström, SA,
)
0.69
"5 million adverse drug reaction (ADR) reports for 8620 drugs/biologics that are listed for 1191 Coding Symbols for Thesaurus of Adverse Reaction (COSTAR) terms of adverse effects."( Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL, 2004
)
0.32

Pharmacokinetics

ExcerptReferenceRelevance
" The pharmacokinetic analysis was made according to a two-compartment open model."( Pharmacokinetics of ampicillin and its prodrugs bacampicillin and pivampicillin in man.
Boréus, LO; Ehrnebo, M; Nilsson, SO, 1979
)
0.52
" The most rapid Tmax and the highest Cmax were achieved with lenampicillin."( Comparative pharmacokinetic study between lenampicillin, bacampicillin and amoxycillin.
Jepson, AP; Sefton, AM; Sum, ZM; Williams, JD, 1989
)
0.52
" The pharmacokinetic analysis was carried out by applying a single-compartment kinetic model with zero-order absorption."( Pharmacokinetics of bacampicillin using a compartment model with zero-order absorption.
Ecari, U; Ferrante, L; Mignini, F; Ripa, S; Ruffilli, MP, 1988
)
0.6
" The rate of penetration of ampicillin into the blister fluid was lower than the rate of gastrointestinal absorption of bacampicillin, and the elimination of ampicillin from the blister fluid was slower than from serum; the half-life in blister fluid was approximately twice that in serum."( Pharmacokinetics of ampicillin in serum and in dermal suction blisters after oral administration of bacampicillin.
Bergan, T; Digranes, A; Hellum, KB; Schreiner, A,
)
0.56

Bioavailability

absolute oral bioavailability was 31, 39, 23, and 2% for pivampicillin, bacampicill, talampicillus, and ampicillin sodium, respectively. A 200-mg amount of bacampsicillin showed a significantly higher relative extent of bioavailability than did a 250- mg amount of talampiillin. The bioavailability of the esters bacAMPicillin (86 +/- 11%) and pivampICillin (92 +/- 18%) was significantly greater than that of Ampicillin.

ExcerptReferenceRelevance
" The bioavailability of the esters bacampicillin (86 +/- 11%) and pivampicillin (92 +/- 18%) was significantly greater than that of ampicillin (62 +/- 17%); however, the difference between the esters was not statistically significant."( Pharmacokinetics of ampicillin and its prodrugs bacampicillin and pivampicillin in man.
Boréus, LO; Ehrnebo, M; Nilsson, SO, 1979
)
0.79
" and oral administration absorption rate of Bacampicillin which is hydrolysed rapidly to Ampicillin in the body was determined as 95%."( [Clinical pharmacology of Bacampicillin in comparison to Ampicillin (author's transl)].
Klaus, M; Malerczyk, V; Simon, C, 1978
)
0.82
" Hypoacidity as such does not reduce the bioavailability of amoxycillin or bacampicillin."( No effect of omeprazole-induced hypoacidity on the bioavailability of amoxycillin or bacampicillin.
Höglund, P; Paulsen, O; Walder, M, 1989
)
0.73
" However, these absorptions were improved enormously by the addition of surface-active agents, that is, an excellent prolonged absorption and high bioavailability were obtained."( Studies on sustained-release suppositories. I. Effect of alginic acid addition on rectal absorption of bacampicillin in rabbits.
Fujiwara, H; Kawashima, S; Nishiura, N; Noguchi, T, 1989
)
0.49
"Rectal absorption of bacampicillin hydrochloride (BAPC) was found to show the best bioavailability with Witepsol H-15 as suppository base among various Witepsol bases."( Studies on sustained-release suppositories. II. Evaluation of polymer electrolyte containing acidic groups for prolonged rectal absorption of bacampicillin in rabbits.
Fujiwara, H; Kawashima, S; Noguchi, T; Sugimura, M, 1989
)
0.8
" We assessed the effect of simultaneous oral administration of NAC on the bioavailability of two antibiotics in ten healthy volunteers."( No effect of oral N-acetylcysteine on the bioavailability of erythromycin and bacampicillin.
Borgström, L; Kågedal, B; Paulsen, O; Walder, M, 1988
)
0.5
" The objective of the study was to compare the in vitro release and bioavailability of bacampicillin hydrochloride from microcapsules coated with two principally different polymers: a water-insoluble polymer, ethylcellulose, and an acid-soluble polymer, Eudragit E 100."( In vitro-in vivo evaluation of bacampicillin hydrochloride from microcapsules of water-insoluble and an acid-soluble polymer.
Nyqvist, H; Sjöqvist, R; Sjövall, J; Westerlund, D,
)
0.64
" Consequently, differences in the relative bioavailability were based on urinary recoveries assuming constant non-renal clearance."( Oral cyclacillin interacts with the absorption of oral ampicillin, amoxycillin, and bacampicillin.
Alván, G; Sjövall, J; Westerlund, D, 1985
)
0.49
"The present study was designed to investigate the effect of food and of a raised intragastric pH on the bioavailability of two prodrug beta-lactam, antibiotics, namely bacampicillin and cefuroxime axetil."( Influence of food and reduced gastric acidity on the bioavailability of bacampicillin and cefuroxime axetil.
Moncrieff, J; Schoeman, HS; Sommers, DK; van Wyk, M, 1984
)
0.69
" This was verified by comparing the predicted plasma response values with the values obtained in a bioavailability study in healthy volunteers."( Linear systems analysis and moment analysis in the evaluation of bacampicillin bioavailability from microcapsule suspensions.
Ellström, K; Nicklasson, M; Sjöqvist, R; Sjövall, J, 1984
)
0.51
"The relative bioavailability of microencapsulated bacampicillin hydrochloride in suspension was correlated with the in vitro dissolution half-lives of the microcapsules."( Correlation between the bioavailability of microencapsulated bacampicillin hydrochloride in suspension and in vitro microcapsule dissolution.
Huitfeldt, B; Nyqvist, H; Sjöqvist, R; Sjövall, J, 1984
)
0.76
"The relative bioavailability of bacampicillin hydrochloride, a pro-drug of ampicillin, was compared after rectal and oral administration."( Rectal bioavailability of bacampicillin hydrochloride in man as determined by reversed-phase liquid chromatography.
Alván, G; Magni, L; Nord, CE; Sjövall, J; Sörstad, J; Westerlund, D, 1984
)
0.85
" The bioavailability of bacampicillin was two-to threefold greater than that of ampicillin."( Comparative pharmacokinetics of bacampicillin and ampicillin suspensions in infants and children.
Clahsen, J; Ginsburg, CM; McCracken, GH; Zweighaft, T,
)
0.72
" It differs from ampicillin in having an ethoxycarbonyloxyethyl group attached to the carboxyl group in C3 of the penicillin nucleus, thus forming an ester with higher bioavailability than ampicillin."( Clinical pharmacokinetic evaluation of bacampicillin.
Braga, PC; Ceccarelli, G; Fraschini, F; Scaglione, F; Scarpazza, G, 1981
)
0.53
"A 200-mg amount of bacampicillin showed a significantly higher relative extent of bioavailability than did a 250-mg amount of talampicillin, possibly due to their different stability in the digestive juices."( Bioavailability of bacampicillin and talampicillin, two oral prodrugs of ampicillin.
Magni, L; Sjövall, J; Vinnars, E, 1981
)
0.92
" When bacampicillin and pivampicillin (two ampicillin prodrugs) were administered to horses, high oral bioavailability was obtained, and the use of prodrugs commands the need for further investigation."( Ampicillin and its congener prodrugs in the horse.
McKellar, QA; Sarasola, P,
)
0.61
"5 mg/kg of body weight to ponies and horses, and was highly bioavailable (F = 41."( Pharmacokinetics of bacampicillin in equids.
McKellar, QA; Sarasola, P, 1995
)
0.61
"Absolute oral bioavailability was 31, 39, 23, and 2% for pivampicillin, bacampicillin, talampicillin, and ampicillin sodium, respectively."( Oral bioavailability and in vitro stability of pivampicillin, bacampicillin, talampicillin, and ampicillin in horses.
Ensink, JM; Fluitman, MA; Tukker, JJ; van Miert, AS; Vulto, AG; Winkel, MB, 1996
)
0.77

Dosage Studied

Bacampicillin was given in a dosage regimen of 400 mg or 800 mg three times daily. Twice daily dosing has been shown in numerous clinical trials to be of equivalent efficacy to ampicillin given four times daily or amoxicillin given three timesdaily.

ExcerptRelevanceReference
" Bacampicillin was given in a dosage regimen of 400 mg or 800 mg three times daily."( Lower respiratory tract infections treated with bacampicillin: a dose comparison.
Sjövall, J, 1977
)
1.42
" The daily dosage was about 40 mg/kg body weight in each case and the duration of treatment was 10 days."( Clinical efficacy and tolerance of bacampicillin and amoxycillin suspensions in children with acute otitis media.
Bondesson, G; Haapaniemi, J; Puhakka, HJ; Tuohimaa, P,
)
0.41
" In most cases a dosage of 400 mg X 2 was used but in severe cases 800 mg X 2 was used."( A multicentre trial with bacampicillin (Penglobe) in the treatment of respiratory tract infections in general practice.
Detiège, JJ; Pauwels, R, 1986
)
0.57
" The aim was to evaluate the efficacy and safety of bacampicillin in a twice daily dosage, compared with three times daily dosages of bacampicillin, ampicillin, amoxycillin and a twice daily dosage of co-trimoxazole."( The clinical efficacy and safety of bacampicillin twice daily in comparative studies.
Blomqvist, M; Hedström, SA,
)
0.66
" All volunteers were dosed with both bacampicillin and cefuroxime axetil under the above regimens."( Influence of food and reduced gastric acidity on the bioavailability of bacampicillin and cefuroxime axetil.
Moncrieff, J; Schoeman, HS; Sommers, DK; van Wyk, M, 1984
)
0.77
"The evaluation of a 10-day 3 x 800 mg dosage regimen was equivalent for bacampicillin to oral ampicillin therapy (using 3 or 4 g respectively per day) in patients with primary UTI (n = 50) in clinical and bacteriological respect."( [Bacampicillin in urinary tract infections tolerance in patients with impaired kidney and liver function].
Ezold, R; Kleint, V; Tauchnitz, C, 1984
)
1.41
" Twice daily dosing (pulse dosing) with bacampicillin has been shown in numerous clinical trials to be of equivalent efficacy to ampicillin given four times daily or amoxicillin given three times daily in the treatment of infections of the upper respiratory tract, lower respiratory tract, skin and soft tissues, and urinary tract."( Bacampicillin hydrochloride: chemistry, pharmacology, and clinical use.
Neu, HC; Scheife, RT,
)
1.84
"The safety and clinical efficacy of dosing twice a day with bacampicillin was evaluated in clinical trials conducted at various locations in Latin America, Switzerland, and Scandinavia, Bacampicillin (200, 400, 600, or 800 mg) given twice a day was compared with bacampicillin (400 mg) or ampicillin (500 or 556 mg) administered three times a day in eight double-blind and six open randomized trials involving 750 patients with respiratory and urinary tract infections."( Worldwide experience with bacampicillin administered twice a day.
Craig, WA; Gerber, AU,
)
0.67
"The purpose of the study was to select the minimum effective dose of bacampicillin in a systematic dose-response study in hospitalised patients with acute exacerbations of chronic bronchitis."( Bacampicillin twice daily: a dose-response study in acute exacerbations of chronic bronchitis.
Davies, BI; Maesen, FP; Sjövall, J, 1981
)
1.94
"The drugs were administered intragastrically to the horses at a dosage equimolar to 15 mg of ampicillin/kg of body weight."( Oral bioavailability and in vitro stability of pivampicillin, bacampicillin, talampicillin, and ampicillin in horses.
Ensink, JM; Fluitman, MA; Tukker, JJ; van Miert, AS; Vulto, AG; Winkel, MB, 1996
)
0.53
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (1)

RoleDescription
prodrugA compound that, on administration, must undergo chemical conversion by metabolic processes before becoming the pharmacologically active drug for which it is a prodrug.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (1)

ClassDescription
penicillanic acid ester
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Bioassays (28)

Assay IDTitleYearJournalArticle
AID1079940Granulomatous liver disease, proven histopathologically. Value is number of references indexed. [column 'GRAN' in source]
AID1079946Presence of at least one case with successful reintroduction. [column 'REINT' in source]
AID588214FDA HLAED, liver enzyme composite activity2004Current drug discovery technologies, Dec, Volume: 1, Issue:4
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID588219FDA HLAED, gamma-glutamyl transferase (GGT) increase2004Current drug discovery technologies, Dec, Volume: 1, Issue:4
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID588216FDA HLAED, serum glutamic oxaloacetic transaminase (SGOT) increase2004Current drug discovery technologies, Dec, Volume: 1, Issue:4
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID1079936Choleostatic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is < 2 (see ACUTE). Value is number of references indexed. [column 'CHOLE' in source]
AID588215FDA HLAED, alkaline phosphatase increase2004Current drug discovery technologies, Dec, Volume: 1, Issue:4
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID1079931Moderate liver toxicity, defined via clinical-chemistry results: ALT or AST serum activity 6 times the normal upper limit (N) or alkaline phosphatase serum activity of 1.7 N. Value is number of references indexed. [column 'BIOL' in source]
AID1079935Cytolytic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is > 5 (see ACUTE). Value is number of references indexed. [column 'CYTOL' in source]
AID588217FDA HLAED, serum glutamic pyruvic transaminase (SGPT) increase2004Current drug discovery technologies, Dec, Volume: 1, Issue:4
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID1079932Highest frequency of moderate liver toxicity observed during clinical trials, expressed as a percentage. [column '% BIOL' in source]
AID1079944Benign tumor, proven histopathologically. Value is number of references indexed. [column 'T.BEN' in source]
AID1079937Severe hepatitis, defined as possibly life-threatening liver failure or through clinical observations. Value is number of references indexed. [column 'MASS' in source]
AID1079939Cirrhosis, proven histopathologically. Value is number of references indexed. [column 'CIRRH' in source]
AID409951Inhibition of human liver MAOB2008Journal of medicinal chemistry, Nov-13, Volume: 51, Issue:21
Quantitative structure-activity relationship and complex network approach to monoamine oxidase A and B inhibitors.
AID588218FDA HLAED, lactate dehydrogenase (LDH) increase2004Current drug discovery technologies, Dec, Volume: 1, Issue:4
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID1079942Steatosis, proven histopathologically. Value is number of references indexed. [column 'STEAT' in source]
AID1079945Animal toxicity known. [column 'TOXIC' in source]
AID1079934Highest frequency of acute liver toxicity observed during clinical trials, expressed as a percentage. [column '% AIGUE' in source]
AID1079933Acute liver toxicity defined via clinical observations and clear clinical-chemistry results: serum ALT or AST activity > 6 N or serum alkaline phosphatases activity > 1.7 N. This category includes cytolytic, choleostatic and mixed liver toxicity. Value is
AID1079947Comments (NB not yet translated). [column 'COMMENTAIRES' in source]
AID1079948Times to onset, minimal and maximal, observed in the indexed observations. [column 'DELAI' in source]
AID1079949Proposed mechanism(s) of liver damage. [column 'MEC' in source]
AID409949Inhibition of human liver MAOA2008Journal of medicinal chemistry, Nov-13, Volume: 51, Issue:21
Quantitative structure-activity relationship and complex network approach to monoamine oxidase A and B inhibitors.
AID1079938Chronic liver disease either proven histopathologically, or through a chonic elevation of serum amino-transferase activity after 6 months. Value is number of references indexed. [column 'CHRON' in source]
AID1079943Malignant tumor, proven histopathologically. Value is number of references indexed. [column 'T.MAL' in source]
AID1079941Liver damage due to vascular disease: peliosis hepatitis, hepatic veno-occlusive disease, Budd-Chiari syndrome. Value is number of references indexed. [column 'VASC' in source]
AID1159607Screen for inhibitors of RMI FANCM (MM2) intereaction2016Journal of biomolecular screening, Jul, Volume: 21, Issue:6
A High-Throughput Screening Strategy to Identify Protein-Protein Interaction Inhibitors That Block the Fanconi Anemia DNA Repair Pathway.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (140)

TimeframeStudies, This Drug (%)All Drugs %
pre-1990119 (85.00)18.7374
1990's13 (9.29)18.2507
2000's7 (5.00)29.6817
2010's1 (0.71)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 39.91

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index39.91 (24.57)
Research Supply Index5.40 (2.92)
Research Growth Index3.89 (4.65)
Search Engine Demand Index59.85 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (39.91)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials44 (24.86%)5.53%
Reviews11 (6.21%)6.00%
Case Studies9 (5.08%)4.05%
Observational0 (0.00%)0.25%
Other113 (63.84%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Clinical Trials (1)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
Prospective Randomized Study to Compare Clinical Outcomes in Patients With Osteomyelitis Treated With Intravenous Antibiotics Versus Intravenous Antibiotics With an Early Switch to Oral Antibiotics [NCT02099240]Early Phase 111 participants (Actual)Interventional2014-03-06Terminated(stopped due to Not enough patient enrollment and lack of staffing)
[information is prepared from clinicaltrials.gov, extracted Sep-2024]